C030019I05Rik Inhibitors
C030019I05Rik, arising from the RIKEN cDNA C030019I05 gene, plays a vital role in cellular processes, potentially involving gene expression regulation. Although direct inhibitors for C030019I05Rik remain undiscovered, exploration into potential inhibitors targeting key signaling pathways provides valuable insights for future investigations. The intricate interplay of C030019I05Rik with pathways such as PI3K-AKT, MAPK/ERK, TGF-β, and JNK underscores the complexity of its regulatory mechanisms. Staurosporine, a versatile kinase inhibitor, exemplifies the diversity of potential inhibitors that could impact C030019I05Rik by modulating essential signaling pathways. SB203580, as a p38 MAP kinase inhibitor, has the potential to indirectly affect C030019I05Rik by disrupting p38 MAP kinase activity, a key regulator implicated in gene expression dynamics. Wortmannin and LY294002, both inhibitors of PI3K, may intricately influence cellular responses associated with C030019I05Rik by disrupting the PI3K-AKT pathway. PD98059, a MEK inhibitor, is envisaged to impact C030019I05Rik by altering the MAPK/ERK pathway. SP600125, a JNK inhibitor, could influence the protein by suppressing c-Jun N-terminal kinase activity, altering cellular stress responses linked to C030019I05Rik.
U0126, SB431542, and SB202190, acting on the MAPK and TGF-β pathways, offer potential avenues for indirectly influencing C030019I05Rik by disrupting key signaling cascades. AZD5363, as an AKT kinase inhibitor, is anticipated to modulate cellular processes linked to C030019I05Rik by altering the PI3K-AKT pathway. VX-745, a JAK2 inhibitor, may impact C030019I05Rik by influencing downstream STAT signaling. Rapamycin, as an mTOR inhibitor, has the potential to alter cellular processes associated with C030019I05Rik, affecting the landscape of gene expression. In conclusion, while direct inhibitors for C030019I05Rik are yet to be identified, the exploration of potential inhibitors targeting pivotal signaling pathways provides a foundation for future investigations. The intricate interplay of C030019I05Rik with pathways such as PI3K-AKT, MAPK/ERK, TGF-β, and JNK necessitates further scrutiny to unravel the specific mechanisms governing its function and potential avenues for modulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor targeting various protein kinases. Its impact on cellular processes may disrupt signaling pathways crucial for C030019I05Rik, potentially influencing gene expression and regulatory mechanisms. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 serves as a p38 MAP kinase inhibitor. Its modulation of the MAPK pathway, particularly p38 MAP kinase, may indirectly affect C030019I05Rik by altering the dynamics of cellular responses associated with this enigmatic protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor. Its disruption of the PI3K-AKT pathway is anticipated to influence cellular processes linked to C030019I05Rik, potentially altering the landscape of gene expression and regulatory mechanisms associated with this protein. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, affecting the MAPK/ERK pathway. Its hypothetical impact on C030019I05Rik involves the inhibition of MEK1, thereby altering the MAPK signaling cascade and influencing the protein's regulatory mechanisms. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, functioning as a PI3K inhibitor is envisaged to intricately influence cellular responses linked to C030019I05Rik by modulating the PI3K-AKT pathway, potentially altering the dynamics of gene expression and regulatory mechanisms associated with this protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, acting as a JNK inhibitor may indirectly influence C030019I05Rik by suppressing c-Jun N-terminal kinase activity. This suppression could impact gene expression dynamics associated with C030019I05Rik by altering cellular stress responses. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a selective inhibitor of the TGF-β type I receptor ALK5. Its modulation of the TGF-β pathway may indirectly impact C030019I05Rik by altering the signaling cascade related to this pathway, potentially influencing the protein's regulatory mechanisms. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190 may indirectly influence C030019I05Rik by disrupting p38 MAP kinase activity. The disruption of this kinase, a key regulator implicated in gene expression dynamics, could impact the regulatory mechanisms of C030019I05Rik. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is an AKT kinase inhibitor. Its modulation of the PI3K-AKT pathway is anticipated to intricately influence cellular processes linked to C030019I05Rik, potentially altering the dynamics of gene expression and regulatory mechanisms associated with this protein. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745 is an envisioned JAK2 inhibitor that targets the JAK-STAT pathway. The speculative influence of VX-745 on C030019I05Rik centers around its capacity to impact downstream STAT signaling, potentially altering the cellular responses linked to the protein's regulatory mechanisms. | ||||||